Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Proteins Identified in Metastatic Kidney Cancer

By LabMedica International staff writers
Posted on 20 Dec 2012
A unique set of proteins have been analyzed that are likely to be involved in the spread of metastatic renal cell carcinoma (RCC). More...


The discovery will help physicians recognize which tumors are going to behave more aggressively and provide those patients with more intensive treatment and closer follow-up.

Scientists collaborating with pathologists at St. Michael's Hospital (Toronto, ON, Canada) used differential proteomics with isobaric tags for relative and absolute quantitation (iTRAQ) labeling and liquid chromatography and mass spectrometry (LC-MS/MS) analysis to identify proteins that are differentially expressed in metastatic compared to primary RCC. Primary RCC tissues and matched normal kidney tissues from the same patient were obtained from nephrectomy specimens at the hospital and processed.

Western blot analysis, tissue microarray construction and immunohistochemistry were also performed. The team identified 29 proteins that change when cancer cells spread from the original site of the kidney tumor and all 29 proteins have been previously been linked to other malignancies. Of these, 12 were overexpressed (iTRAQ ratios of equal or greater than 1.5) and 17 were under expressed (iTRAQ ratios of equal to or less than 0.67).

The authors concluded that through quantitative proteomic analysis, they had identified differential protein expressions that can distinguish between aggressive and nonaggressive RCC tumors. Many of these proteins are involved in biological pathways pertinent to tumor progression and metastasis. In addition, their preliminary analysis showed that some of these dysregulated proteins may be useful clinical markers and validation of these markers would greatly improve RCC patient treatment and increase overall survival.

George M. Yousef, MD, PhD, the senior author of the study, said “Metastatic renal cell carcinoma is one of the most treatment-resistant malignancies and patients have dismal prognosis. Identification of markers that can predict the potential of metastases will have a great impact on improvement patient outcomes." The study was published on October 17, 2012, in the journal Molecular & Cellular Proteomics.

Related Links:

St. Michael's Hospital




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.